Magnetic colloids as drug vehicles

被引:164
作者
Duran, J. D. G. [1 ]
Arias, J. L. [2 ]
Gallardo, V. [2 ]
Delgado, A. V. [1 ]
机构
[1] Univ Granada, Fac Ciencias, Dept Fis Aplicada, E-18071 Granada, Spain
[2] Univ Granada, Fac Pharm, Dept Pharm & Pharmaceut Technol, E-18071 Granada, Spain
关键词
biocompatibility; cancer treatment; core/shell particles; drug vectors; ferrofluids; magnetic composites; magnetic guidance; magnetic drug delivery systems; toxicity;
D O I
10.1002/jps.21249
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
This review article is a description of the present status of magnetic drug delivery systems (DDS). These are colloidal dispersions of composite nanoparticles consisting of a (polymeric or inorganic) biocompatible matrix and magnetic units, and designed to load and release therapeutic drugs. The matrix, together perhaps with adsorbed polymers or polyelectrolytes, provides the DDS with additional colloidal stability and eventually control of the immune response, and the magnetic inclusions have the goal of providing magnetic guidance. The techniques used in the production of the particles are described. The large surface/volume ratio of the particles brings about a superlative importance of the interface aspects, which are depicted in some detail. Attention is also paid to the possibilities that magnetic DDS offer to be guided by magnetic fields, and to their fate upon entering in contact with the blood proteins and the tumor cells. A description of in vitro and in vivo biodistribution experiments helps in this description. The number of animal experiments performed using magnetic DDS is rather large, but results in humans are far from being sufficient in number, something easily understood. The hopes for improvement and the challenges that must be overcome are described in the closing section. (C) 2007 Wiley-Liss, Inc. and the American Pharmacists Association.
引用
收藏
页码:2948 / 2983
页数:36
相关论文
共 153 条
[1]  
Adamson A., 1990, PHYSICAL CHEM SURFAC
[2]  
Alexiou C, 2002, LECT NOTES PHYS, V594, P233
[3]   In vitro and in vivo investigations of targeted chemotherapy with magnetic nanoparticles [J].
Alexiou, C ;
Jurgons, R ;
Schmid, R ;
Hilpert, A ;
Bergemann, C ;
Parak, F ;
Iro, H .
JOURNAL OF MAGNETISM AND MAGNETIC MATERIALS, 2005, 293 (01) :389-393
[4]   Magnetic drug targeting: biodistribution and dependency on magnetic field strength [J].
Alexiou, C ;
Schmidt, A ;
Klein, R ;
Hulin, P ;
Bergemann, C ;
Arnold, W .
JOURNAL OF MAGNETISM AND MAGNETIC MATERIALS, 2002, 252 (1-3) :363-366
[5]  
Alexiou C, 2000, CANCER RES, V60, P6641
[6]   Magnetic mitoxantrone nanoparticle detection by histology, X-ray and MRI after magnetic tumor targeting [J].
Alexiou, C ;
Arnold, W ;
Hulin, P ;
Klein, RJ ;
Renz, H ;
Parak, FG ;
Bergemann, C ;
Lübbe, AS .
JOURNAL OF MAGNETISM AND MAGNETIC MATERIALS, 2001, 225 (1-2) :187-193
[7]   A high field gradient magnet for magnetic drug targeting [J].
Alexiou, Christoph ;
Diehl, Dirk ;
Henninger, Peter ;
Iro, Heinrich ;
Roeckelein, Rudolf ;
Schmidt, Wolfgang ;
Weber, Horst .
IEEE TRANSACTIONS ON APPLIED SUPERCONDUCTIVITY, 2006, 16 (02) :1527-1530
[8]   Targeting cancer cells: magnetic nanoparticles as drug carriers [J].
Alexiou, Christoph ;
Schmid, Roswitha J. ;
Jurgons, Roland ;
Kremer, Marcus ;
Wanner, Gerhard ;
Bergemann, Christian ;
Huenges, Ernst ;
Nawroth, Thomas ;
Arnold, Wolfgang ;
Parak, Fritz G. .
EUROPEAN BIOPHYSICS JOURNAL WITH BIOPHYSICS LETTERS, 2006, 35 (05) :446-450
[9]   Drug delivery systems: Entering the mainstream [J].
Allen, TM ;
Cullis, PR .
SCIENCE, 2004, 303 (5665) :1818-1822
[10]   Development of carbonyl iron/ethylcellulose core/shell nanoparticles for biomedical applications [J].
Arias, J. L. ;
Lopez-Viota, M. ;
Ruiz, M. A. ;
Lopez-Viota, J. ;
Delgado, A. V. .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2007, 339 (1-2) :237-245